QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:NKTR

Nektar Therapeutics (NKTR) Stock Price, News & Analysis

$0.93
+0.05 (+5.55%)
(As of 04:22 PM ET)
Today's Range
$0.86
$0.94
50-Day Range
$0.51
$0.96
52-Week Range
$0.41
$1.12
Volume
1.32 million shs
Average Volume
1.61 million shs
Market Capitalization
$171.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

Nektar Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
274.7% Upside
$3.50 Price Target
Short Interest
Healthy
1.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.94mentions of Nektar Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$19,752 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.93) to ($0.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.36 out of 5 stars

Medical Sector

152nd out of 938 stocks

Pharmaceutical Preparations Industry

58th out of 425 stocks

NKTR stock logo

About Nektar Therapeutics Stock (NASDAQ:NKTR)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

NKTR Stock Price History

NKTR Stock News Headlines

Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Q4 2023 Nektar Therapeutics Earnings Call
Nektar Therapeutics Q4 Loss decreases, but misses estimates
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Nektar Therapeutics earnings: here's what Wall Street expects
Nektar Therapeutics Earnings Preview
DiaMedica Appoints Lorianne Masuoka As Chief Medical Officer
See More Headlines
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/04/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:NKTR
CUSIP
64026810
Employees
216
Year Founded
1990

Price Target and Rating

Average Stock Price Target
$3.50
High Stock Price Target
$6.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+295.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-276,060,000.00
Net Margins
-306.31%
Pretax Margin
-306.54%

Debt

Sales & Book Value

Annual Sales
$90.12 million
Book Value
$0.69 per share

Miscellaneous

Free Float
177,981,000
Market Cap
$162.49 million
Optionable
Optionable
Beta
0.86

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Howard W. RobinMr. Howard W. Robin (Age 71)
    CEO, President & Director
    Comp: $1.83M
  • Mr. Mark A. Wilson (Age 52)
    Senior VP, Chief Legal Officer & Secretary
    Comp: $749.99k
  • Vivian Wu
    Director of Investor Relations & Corporate Affairs
  • Mr. Robert Bacci
    Senior Vice President of Human Resources & Facilities Operations
  • Ms. Jennifer Ruddock
    Chief Business Officer
  • Dr. Mary Tagliaferri L.Ac. (Age 58)
    M.D., Chief Medical Officer
  • Dr. Loui T. Madakamutil
    VP and Head of Discovery & Research

NKTR Stock Analysis - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View NKTR analyst ratings
or view top-rated stocks.

What is Nektar Therapeutics' stock price target for 2024?

5 Wall Street analysts have issued 12-month price objectives for Nektar Therapeutics' stock. Their NKTR share price targets range from $1.00 to $6.00. On average, they predict the company's share price to reach $3.50 in the next year. This suggests a possible upside of 274.7% from the stock's current price.
View analysts price targets for NKTR
or view top-rated stocks among Wall Street analysts.

How have NKTR shares performed in 2024?

Nektar Therapeutics' stock was trading at $0.5650 at the beginning of 2024. Since then, NKTR stock has increased by 65.3% and is now trading at $0.9342.
View the best growth stocks for 2024 here
.

Are investors shorting Nektar Therapeutics?

Nektar Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,510,000 shares, an increase of 24.9% from the February 29th total of 2,010,000 shares. Based on an average trading volume of 1,590,000 shares, the short-interest ratio is currently 1.6 days. Currently, 1.4% of the shares of the company are short sold.
View Nektar Therapeutics' Short Interest
.

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our NKTR earnings forecast
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings data on Monday, March, 4th. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.01. The biopharmaceutical company had revenue of $23.89 million for the quarter, compared to analysts' expectations of $17.09 million. Nektar Therapeutics had a negative net margin of 306.31% and a negative trailing twelve-month return on equity of 96.80%. During the same period last year, the business earned ($0.32) earnings per share.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.31%), Vanguard Group Inc. (6.56%), Primecap Management Co. CA (3.67%), Monaco Asset Management SAM (3.13%), GSA Capital Partners LLP (2.76%) and Assenagon Asset Management S.A. (1.29%). Insiders that own company stock include Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, Robert Chess and Roy A Whitfield.
View institutional ownership trends
.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NKTR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners